Janux Therapeutics Quarterly Income Statements Chart
Quarterly
|
Annual
Janux Therapeutics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| collaboration revenue | 439,000 | 8,897,000 | 1,252,000 | 2,461,000 | 2,517,000 | 1,057,000 | 2,048,000 | 2,845,000 | 1,813,000 | 2,365,000 | 1,589,000 | 1,616,000 | 1,159,000 | 482,000 | |||
| operating expenses: | |||||||||||||||||
| research and development | 34,664,000 | 25,055,000 | 20,806,000 | 18,614,000 | 14,898,000 | 14,070,000 | 12,241,000 | 11,892,000 | 14,924,000 | 15,865,000 | 15,434,000 | 13,737,000 | 14,086,000 | 10,184,000 | 11,169,000 | 8,406,000 | 4,737,000 |
| general and administrative | 10,454,000 | 9,842,000 | 8,216,000 | 17,667,000 | 7,821,000 | 7,343,000 | 6,357,000 | 6,438,000 | 6,881,000 | 6,464,000 | 5,677,000 | 6,098,000 | 5,540,000 | 4,947,000 | 3,937,000 | 3,656,000 | 1,997,000 |
| total operating expenses | 45,118,000 | 34,897,000 | 29,022,000 | 36,281,000 | 22,719,000 | 21,413,000 | 18,598,000 | 18,330,000 | 21,805,000 | 22,329,000 | 21,111,000 | 19,835,000 | 19,626,000 | 15,131,000 | 15,106,000 | 12,062,000 | 6,734,000 |
| income from operations | -45,118,000 | -34,897,000 | -29,022,000 | -35,842,000 | -13,822,000 | -20,161,000 | -16,137,000 | -15,813,000 | -20,748,000 | -20,281,000 | -18,266,000 | -18,022,000 | -17,261,000 | -13,542,000 | -13,490,000 | -10,903,000 | -6,252,000 |
| yoy | 226.42% | 73.09% | 79.85% | 126.66% | -33.38% | -0.59% | -11.66% | -12.26% | 20.20% | 49.76% | 35.40% | 65.29% | 176.09% | ||||
| qoq | 29.29% | 20.24% | -19.03% | 159.31% | -31.44% | 24.94% | 2.05% | -23.79% | 2.30% | 11.03% | 1.35% | 4.41% | 27.46% | 0.39% | 23.73% | 74.39% | |
| operating margin % | |||||||||||||||||
| other income: | |||||||||||||||||
| interest income | 11,260,000 | 11,389,000 | 8,806,000 | 7,783,000 | 7,863,000 | 5,401,000 | 4,379,000 | 4,245,000 | 3,240,000 | 2,822,000 | 2,201,000 | 1,326,000 | 373,000 | 132,000 | 74,000 | 137,000 | 46,000 |
| total other income | 11,260,000 | 11,389,000 | 8,806,000 | 7,783,000 | 7,863,000 | 5,401,000 | 4,379,000 | 4,245,000 | 3,240,000 | 2,822,000 | 2,201,000 | 1,326,000 | 373,000 | 132,000 | 74,000 | 137,000 | 46,000 |
| net income | -33,858,000 | -23,508,000 | -20,216,000 | -28,059,000 | -5,959,000 | -14,760,000 | -11,758,000 | -11,568,000 | -17,508,000 | -17,459,000 | -16,065,000 | -16,696,000 | -16,888,000 | -13,410,000 | -13,416,000 | -10,766,000 | -6,206,000 |
| yoy | 468.18% | 59.27% | 71.93% | 142.56% | -65.96% | -15.46% | -26.81% | -30.71% | 3.67% | 30.19% | 19.75% | 55.08% | 172.12% | ||||
| qoq | 44.03% | 16.28% | -27.95% | 370.87% | -59.63% | 25.53% | 1.64% | -33.93% | 0.28% | 8.68% | -3.78% | -1.14% | 25.94% | -0.04% | 24.61% | 73.48% | |
| net income margin % | |||||||||||||||||
| other comprehensive gain: | |||||||||||||||||
| unrealized gain on available-for-sale securities | -9,000 | 1,593,000 | -5,668,000 | 9,447,000 | -1,092,000 | -1,189,000 | 1,840,000 | -115,000 | -321,000 | 796,000 | -501,750 | -370,000 | -340,000 | -294,000 | 7,000 | -17,000 | |
| comprehensive loss | -33,867,000 | -21,915,000 | -25,884,000 | -18,612,000 | -7,051,000 | -15,949,000 | -9,918,000 | -11,683,000 | -17,829,000 | -16,663,000 | -15,323,000 | -17,066,000 | -17,228,000 | -14,977,000 | -13,710,000 | -10,759,000 | -6,223,000 |
| net income per common share, basic and diluted | -550 | -380 | -350 | -510 | -110 | -300 | -240 | -250 | -420 | -420 | -390 | -400 | -410 | -320 | -290 | -260 | -620 |
| weighted-average shares of common stock outstanding, basic and diluted | 61,902,411,000 | 61,791,721,000 | 53,751,480,000 | 54,628,670,000 | 54,451,666,000 | 49,049,741,000 | 44,016,283,000 | 45,708,649,000 | 41,836,238,000 | 41,763,971,000 | 41,469,631,000 | 41,526,524,000 | 41,448,743,000 | 41,315,482,000 | 23,530,252,000 | 41,134,102,000 | 10,033,328,000 |
| other comprehensive loss: | |||||||||||||||||
| unrealized loss on available-for-sale securities | -1,567,000 | ||||||||||||||||
| interest expense – related parties | |||||||||||||||||
| change in fair value of convertible promissory notes – related parties | |||||||||||||||||
| increase in fair value of convertible promissory notes – related parties |
We provide you with 20 years income statements for Janux Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Janux Therapeutics stock. Explore the full financial landscape of Janux Therapeutics stock with our expertly curated income statements.
The information provided in this report about Janux Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.